2398 completed, 236 unknown, 184 terminated, 126 withdrawn. 3111 Phase 1, 687 Phase 2.
Follow RNA Virus Infections: new trials by email Literature Review of RNA Virus Infections trials Research Report on RNA Virus Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety & Immunogenicity of 426c.Mod.Core-C4b Vaccine With 3M-052-AF+Alum in Infants Perinatally Exposed to HIV But Uninfected 426c.Mod.Core-C4b, 3M-052-AF, Aluminum hydroxide suspension (Alum) - HIV Infections | Phase 1 | Not yet recruiting | HIV Vaccine Trials Network | 22 | 2027-03-30 | 2026-09-18 |
| A Phase 1 Clinical Trial of Adjuvanted Protein-based HCV Vaccine Candidates (HCV Vaccine Trial) AVIHepC1, Normal Saline - Hepatitis C | Phase 1 | Not yet recruiting | University of Alberta | 27 | 2027-01-15 | 2026-09-25 |
| Phase I Study of VLPDEN-02 Dengue Vaccine in Healthy Adults VLPDEN-02 1.0 µg (0.25 µg of each VLP) + ALFQ adjuvant, VLPDEN-02 10 µg (2.5 µg of each VLP) + ALFQ adjuvant, VLPDEN-02 100 µg (25 µg of each VLP) + ALFQ adjuvant - Randomised Clinical Trial, Double Blind | Phase 1 | Not yet recruiting | VLP Therapeutics | 42 | 2027-01-04 | 2026-09-21 |
| Evaluation of the Safety and Efficacy of XoGlo Pro, a Placental Mesenchymal Stem Cell-derived Extracellular Vesicles in Treating COVID-19 Symptoms IV infusion using an isolated, placental, mesenchymal stem cell derived EVs, Placebo IV administration - COVID-19 | Phase 1 / Phase 2 | Not yet recruiting | Kimera Labs Inc. | 64 | 2027-01-01 | 2026-06-24 |
| Safety and Immunogenicity of VPM1002 Vaccination or BCG Revaccination Against TB in Pre-Adolescents Living With and Without HIV in South Africa VPM1002 Vaccine, BCG Vaccine, Placebo - Tuberculosis, HIV Infections | Phase 1 / Phase 2 | Withdrawn | International Maternal Pediatric Adolescent AIDS Clinical Trials Group | 2026-12-31 | 2026-08-17 | |
| Taurine Supplementation in Adolescents With Post-COVID Condition Taurine - Long COVID, Post COVID-19 Condition | Phase 1 / Phase 2 | Not yet recruiting | University of Alberta | 30 | 2026-12-30 | 2026-10-16 |
| A Study to Describe the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine IN006 in Healthy Adults Bivalent RSV Vaccine (IN006), Placebo - Respiratory Syncytial Virus Infections | Phase 1 | Not yet recruiting | Shenzhen Shenxin Biotechnology Co., Ltd | 200 | 2026-12-01 | 2026-04-13 |
| Use of ACU-D1 in HPV Associated Vulvar and Perianal Lesions in People With HIV Dose Level 1 ACU-D1 ointment, Dose Level 2 ACU-D1 ointment, Dose Level 3 ACU-D1 ointment - Human Papilloma Virus, Human Immunodeficiency Virus | Phase 1 | Not yet recruiting | Emory University | 9 | 2026-12-01 | 2026-08-18 |
| Evaluating AVM0703 for Treatment of COVID-19 or Influenza-mediated ARDS AVM0703, Placebo - ARDS, Covid19 | Phase 1 | Not yet recruiting | AVM Biotechnology Inc | 16 | 2026-12-01 | 2025-10-02 |
| Pancoronavirus Vaccine Study in Healthy Adults Ages 18-55 Cov-RBD-scNP-001, ACU-026-001-1 - Coronavirus Infection | Phase 1 | Not yet recruiting | Duke University | 36 | 2026-11-16 | 2026-10-29 |
| A Study to Investigate Safety, Tolerability and Pharmacokinetics of VH5356136 in Adult Participants Without HIV VH5356136 Formulation 1, VH5356136 Formulation 2, Placebo for VH5356136 Formulation 1 - HIV Infections | Phase 1 | Not yet recruiting | ViiV Healthcare | 160 | 2026-11-06 | 2026-09-16 |
| Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I) Keytruda - Post-Acute COVID-19 Syndrome | Phase 1 | Not yet recruiting | National Institute of Neurological Disorders and Stroke (NINDS) | 15 | 2026-11-04 | 2026-10-30 |
| A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine RVX-sCPD9 - COVID -19 | Phase 1 | Not yet recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 80 | 2026-10-17 | 2026-10-30 |
| A Clinical Study to Evaluate the Safety and Immunogenicity of a Higher Dose of the Study Vaccine, VIR-1388, in HCMV-seropositive Adult Participants Without HIV VIR-1388, Placebo - Cytomegalovirus (CMV), HIV (Human Immunodeficiency Virus) | Phase 1 | Not yet recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 12 | 2026-10-15 | 2026-09-03 |
| A Phase I/II Clinical Trial of the Diphtheria, Tetanus, Acellular Component Pertussis and Sabin Inactivated Poliomyelitis Vaccine Adsorbed Diphtheria, Tetanus, Acellular Component Pertussis and Sabin Inactivated Poliomyelitis Vaccine Adsorbed, Diphtheria, Tetanus and Acellular Component Pertussis Combined Vaccine, Diphtheria, Tetanus and Acellular Component Pertussis Combined Vaccine+Inactivated Poliomyelitis Vaccine Made From Sabin Strains - Diphtheria, Pertussis | Phase 1 / Phase 2 | Recruiting | Institute of Medical Biology, Chinese Academy of Medical Sciences | 380 | 2026-10-11 | 2026-10-23 |
| Safety and Immunogenicity of Chimeric Hemagglutinin mRNA Vaccine Candidates cH15/3, cH4/3, cH5/1N1 - Influenza | Phase 1 | Not yet recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 60 | 2026-10-09 | 2026-10-30 |
| A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Children mRNA-1010, Fluarix Trivalent - Seasonal Influenza | Phase 1 | Recruiting | ModernaTX, Inc. | 96 | 2026-10-07 | 2026-10-28 |
| Safety, Tolerability, and Immunogenicity of BMI2012 Against COVID-19 Variant in Healthy Adults Aged 19 and 55 Years BMI2012 low-dose, Placebo low-dose, BMI2012 mid-dose - Prevention of COVID-19 Variant (Omicron JN.1) | Phase 1 | Not yet recruiting | BMI Korea | 72 | 2026-10-01 | 2026-08-28 |
| A Trial to Evaluate the Safety, Immunogenicity and the Optimal Dose of MOPEVAC-Las Vaccine Candidate Against Lassa Fever Low dose MOPEVAC-Las vaccine, Intermediate dose MOPEVAC-Las vaccine, High dose MOPEVAC-Las vaccine - Lassa Fever | Phase 1 | Recruiting | Institut Pasteur | 72 | 2026-09-28 | 2026-10-13 |
| A Study to Investigate Pharmacokinetics (PK), Safety, and Tolerability of VH4367310 in Healthy Adult Participants VH4367310, Placebo - HIV Infections | Phase 1 | Recruiting | ViiV Healthcare | 112 | 2026-09-15 | 2026-10-20 |
Showing 20 of 3111. Sign in to see all of them.
HIV Infections (998) · COVID-19 (675) · Acquired Immunodeficiency Syndrome (507) · Influenza, Human (395) · Hepatitis C (266) · Coronavirus Infections (124) · Infections (111) · Hepatitis C, Chronic (105) · Respiratory Syncytial Virus Infections (105) · Virus Diseases (103) · AIDS-Related Complex (102) · Dengue (63) · Influenza in Birds (53) · Hemorrhagic Fever, Ebola (46) · Respiratory Distress Syndrome (35)
Virus Diseases (3008) · Infections (3000) · Blood-Borne Infections (1585) · Communicable Diseases (1582) · Immune System Diseases (1270) · Urogenital Diseases (1269) · Genital Diseases (1262) · Retroviridae Infections (1259) · Immunologic Deficiency Syndromes (1256) · Lentivirus Infections (1255) · Sexually Transmitted Diseases, Viral (1255) · Sexually Transmitted Diseases (1248) · Respiratory Tract Diseases (1122) · Respiratory Tract Infections (1085)
Ritonavir (95) · Zidovudine (68) · Sodium Chloride (60) · Influenza Vaccines (52) · Saline Solution (51) · Ribavirin (37) · dolutegravir (37) · Didanosine (29) · Lamivudine (28) · Vaccines (28) · Nevirapine (26) · Raltegravir Potassium (26) · Simeprevir (26) · Aluminum Hydroxide (24) · efavirenz (24)
National Institute of Allergy and Infectious Diseases (NIAID) (621) · ViiV Healthcare (124) · GlaxoSmithKline (71) · Merck Sharp & Dohme LLC (66) · Pfizer (50) · Bristol-Myers Squibb (46) · Tibotec Pharmaceuticals, Ireland (39) · National Cancer Institute (NCI) (31) · University of Oxford (30) · Gilead Sciences (28) · Sanofi Pasteur, a Sanofi Company (28) · Boehringer Ingelheim (25) · International AIDS Vaccine Initiative (25) · International Partnership for Microbicides, Inc. (21) · Hoffmann-La Roche (19)
United States (1709) · China (176) · United Kingdom (140) · Australia (92) · Puerto Rico (87) · South Africa (87) · Belgium (82) · Germany (73) · Canada (71) · Brazil (50) · Spain (49) · Thailand (49) · Netherlands (44) · France (43) · Russia (41)
Anna Durbin, MD (29) · Ruth A. Karron, MD (17) · Belshe R (9)
PMID 34473343, PMID 40190112, PMID 25820067, PMID 23349878, PMID 34817414, PMID 34843602, PMID 35713300, PMID 36435633, PMID 37231296, PMID 22288567, PMID 26383952, PMID 26432909, PMID 29217375, PMID 31986264, PMID 32838558, PMID 34895272, PMID 36147329, PMID 16148846, PMID 16220994, PMID 18090046, PMID 19118378, PMID 19540952, PMID 21488067, PMID 21906647, PMID 21975270, PMID 22242162, PMID 22336878, PMID 22426327, PMID 22542645, PMID 22900504, PMID 22914365, PMID 24260259, PMID 25114140, PMID 25296098, PMID 25426834, PMID 25801652, PMID 25830326, PMID 26042486, PMID 26275339, PMID 26332605, PMID 26391974, PMID 26424605, PMID 26458804, PMID 26546548, PMID 26659569, PMID 27098021, PMID 27535056, PMID 28017642, PMID 28647166, PMID 29509911
2009 (12), 2008 (11), U01CA121947 (11), 2015 (10), 2023 (10), 2014 (9), 2018 (8), 2017 (7), 2019 (7), UM1CA121947 (6), 2025 (5), 2016 (4), U19AI057229 (4), UM1AI068614 (4), 2005 (2)